Download PDF
Onkologische Welt 2017; 08(03): 112-114
DOI: 10.1055/s-0038-1639669
St. Gallen Brustkrebs
Schattauer GmbH

Deeskalation der Brustkrebs - therapie – ist weniger mehr?

St. Gallen International Breast Cancer Conference 2017
Thomas M. Heim Dr.
Further Information

Publication History

Publication Date:
10 March 2018 (online)

Also available at
    Permissions and Reprints

Das Stichwort Deeskalation war bei der diesjährigen St. Gallen International Breast Cancer Conference in aller Munde. Brusterhaltende Operationen und niedriger dosierte Strahlenbehandlungen sind bereits Standard. Sie zeigen, dass Deeskalation gelingen kann, ohne die Wirksamkeit der Therapie aufs Spiel zu setzen und mit erheblichem Gewinn für das Wohlbefinden der Patientin. Um zu rationalen Deeskalationsstrategien in der systemischen Therapie zu gelangen, wäre eine stärkere Vernetzung der Forschungsaktivitäten notwendig.

 

  • Literatur

  • 1 Cameron D. et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HER- ceptin Adjuvant (HERA) trial. Lancet 2017; 389: 1195-1205.
    CrossrefPubMedGoogle Scholar
  • 2 Cardoso F. et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.
    CrossrefPubMedGoogle Scholar
  • 3 Giuliano AE. et al. Ten-year survival results of ACO- SOG Z0011: A randomized trial of axillary node dissection in women with clinical T1—2 NO M0 breast cancer who have a positive sentinel node (Alliance).. J Clin Oncol 34. 2016 (suppl; abstr 1007)
    PubMedGoogle Scholar
  • 4 Boughey JC. et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310: 1455-61.
    CrossrefPubMedGoogle Scholar
  • 5 Kuehn T. et al. Sentinel-lymph-node biopsy with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective multicenter cohort study. Lancet Oncol 2013; 14: 609-618.
    CrossrefPubMedGoogle Scholar
  • 6 Boileau JF. et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015; 33: 258-264.
    PubMedGoogle Scholar
  • 7 Petruolo OA. et al. Can Standard Pathologic Features be Used to Identify a Subset of Estrogen Positive HER2 Negative Tumors Likely to Benefit from Neoadjuvant Chemotherapy?. Society of Surgical Oncology 70th Annual Cancer Symposium 2017. Abstract 11
    Google Scholar
  • 8 Pilewskie M. et al. The optimal treatment plan to avoid axillary lymph node dissection in early stage breast cancer patients differs by tumor subtype.. Society of Surgical Oncology 70th Annual Cancer Symposium 2017, Abstract PF56
    Google Scholar